Alexion Pharmaceuticals Inc. [NASDAQ: ALXN] price surged by 0.35 percent to reach at $0.37. The company report on July 30, 2020 that Alexion Reports Second Quarter 2020 Results.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the second quarter of 2020. Total revenues in the second quarter were $1,444.6 million, a 20 percent increase compared to the same period in 2019. The negative impact of foreign currency on total revenues year-over-year was 1 percent, or $15.9 million, inclusive of hedging activities. On a GAAP basis, diluted EPS in the quarter was $(4.84), compared to $2.04 in the prior year. The second quarter of 2020 includes impairment charges of $2,053.3 million primarily relating to the KANUMA intangible asset as a result of the Company’s revised strategic view of KANUMA. Non-GAAP diluted EPS for the second quarter of 2020 was $3.11, an 18 percent increase versus the second quarter of 2019.
“Our teams have demonstrated remarkable resilience and agility in their successful navigation of the uncertain COVID-19 pandemic environment. Despite these challenges, we have delivered another strong quarter and continue to advance our LEAD-EXPAND-DIVERSIFY strategy for long-term value creation,” said Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion. “As a result of execution and delivery against our objectives, we have entered a new phase of company growth and diversification, which enables us to adjust our capital allocation priorities and return value to shareholders through an expanded stock buyback program. I am incredibly proud of what we have accomplished so far and am confident that we are well positioned to build on this momentum in the second half of the year.”.
A sum of 1546620 shares traded at recent session while its average daily volume was at 2.06M shares. Alexion Pharmaceuticals Inc. shares reached a high of $105.30 and dropped to a low of $103.14 until finishing in the latest session at $105.22.
The one-year ALXN stock forecast points to a potential upside of 25.4. The average equity rating for ALXN stock is currently 2.10, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Alexion Pharmaceuticals Inc. [ALXN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ALXN shares is $141.05 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ALXN stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
William Blair have made an estimate for Alexion Pharmaceuticals Inc. shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on July 31, 2020. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Neutral. The new note on the price target was released on April 28, 2020, representing the official price target for Alexion Pharmaceuticals Inc. stock. On March 05, 2020, analysts decreased their price target for ALXN shares from 130 to 110.
The Average True Range (ATR) for Alexion Pharmaceuticals Inc. is set at 3.08, with the Price to Sales ratio for ALXN stock in the period of the last 12 months amounting to 4.29. The Price to Book ratio for the last quarter was 2.21, with the Price to Cash per share for the same quarter was set at 12.63. Price to Free Cash Flow for ALXN in the course of the last twelve months was 10.04 with Quick ratio for the last quarter at 4.30.
ALXN Stock Performance Analysis:
Alexion Pharmaceuticals Inc. [ALXN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.01. With this latest performance, ALXN shares dropped by -7.35% in over the last four-week period, additionally plugging by 2.21% over the last 6 months – not to mention a drop of -2.48% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALXN stock in for the last two-week period is set at 44.26, with the RSI for the last a single of trading hit 45.98, and the three-weeks RSI is set at 46.16 for Alexion Pharmaceuticals Inc. [ALXN]. The present Moving Average for the last 50 days of trading for this stock 110.93, while it was recorded at 104.39 for the last single week of trading, and 104.60 for the last 200 days.
Insight into Alexion Pharmaceuticals Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Alexion Pharmaceuticals Inc. [ALXN] shares currently have an operating margin of +42.45 and a Gross Margin at +85.79. Alexion Pharmaceuticals Inc.’s Net Margin is presently recorded at +48.53.
Return on Total Capital for ALXN is now 15.93, given the latest momentum, and Return on Invested Capital for the company is 18.56. Return on Equity for this stock inclined to 23.53, with Return on Assets sitting at 15.28. When it comes to the capital structure of this company, Alexion Pharmaceuticals Inc. [ALXN] has a Total Debt to Total Equity ratio set at 24.46. Additionally, ALXN Total Debt to Total Capital is recorded at 19.66, with Total Debt to Total Assets ending up at 15.72. Long-Term Debt to Equity for the company is recorded at 23.17, with the Long-Term Debt to Total Capital now at 18.62.
Reflecting on the efficiency of the workforce at the company, Alexion Pharmaceuticals Inc. [ALXN] managed to generate an average of $780,110 per employee. Receivables Turnover for the company is 4.58 with a Total Asset Turnover recorded at a value of 0.31.Alexion Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.30 and a Current Ratio set at 4.80.
ALXN Stock EPS
With the latest financial reports released by the company, Alexion Pharmaceuticals Inc. posted 2.79/share EPS, while the average EPS was predicted by analysts to be reported at 2.47/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 13.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ALXN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Alexion Pharmaceuticals Inc. go to 11.88%.
Alexion Pharmaceuticals Inc. [ALXN] Insider Position Details
There are presently around $21,185 million, or 93.50% of ALXN stock, in the hands of institutional investors. The top three institutional holders of ALXN stocks are: VANGUARD GROUP INC with ownership of 17,178,711, which is approximately 2.471% of the company’s market cap and around 0.30% of the total institutional ownership; BLACKROCK INC., holding 16,510,976 shares of the stock with an approximate value of $1.74 billion in ALXN stocks shares; and FMR LLC, currently with $1.25 billion in ALXN stock with ownership of nearly -19.12% of the company’s market capitalization.
Positions in Alexion Pharmaceuticals Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 356 institutional holders increased their position in Alexion Pharmaceuticals Inc. [NASDAQ:ALXN] by around 22,168,073 shares. Additionally, 344 investors decreased positions by around 24,423,847 shares, while 70 investors held positions by with 154,748,247 shares. The mentioned changes placed institutional holdings at 201,340,167 shares, according to the latest SEC report filing. ALXN stock had 99 new institutional investments in for a total of 5,208,193 shares, while 88 institutional investors sold positions of 1,751,412 shares during the same period.